San Diego, CA
March 2026
$3-5M
CONFIDENTIAL
Table of Contents
01
Section 01
The Market Opportunity
The peptide wellness market is massive and accelerating across every segment.
US Compounding Pharmacy
By 2034 (from $6.7B in 2025); 503B growing at 7.63% CAGR — fastest segment
Global Peptide Therapeutics
By 2035 (from $52.6B); US alone projected at $160.3B by 2030 at 16.2% CAGR
US Medical Spa Market
By 2035 (from $8.4B); 14% CAGR; 24% uptick in membership sales in 2024
Cosmetic Peptide Skincare
By 2033 (from $2.62B); 12.3% CAGR; GHK-Cu alone projected at $594M–$1.6B by 2032

Cash-pay compounding pharmacies achieve 40–60% gross margins vs. 22% retail. D2C telehealth peptide brands reaching $5–25M+ annual revenue within 1–2 years.
Section 02
The Regulatory Landscape — A Critical Shift
The FDA enforcement environment has fundamentally changed. The grey-market model is collapsing — but for licensed, compliant pharmacies, this is a once-in-a-decade opportunity. Competitors are leaving while demand grows.
Enforcement Actions (2024–2026)
  • 50+ FDA warning letters to peptide companies (Sept 2025 alone)
  • 30 warning letters to telehealth companies (Dec 2024)
  • 40+ state AGs coordinating enforcement nationally
  • Tailor Made Compounding: $1.79M forfeiture, owner 3yr probation
  • All American Peptide: $3M+ forfeiture, guilty plea
  • Peptide Sciences ($7.4M/month) voluntarily shut down March 6, 2026
  • Courts rejected "research use only" disclaimers as a "ruse"
19 Peptides Moved to Category 2 (BANNED)
BPC-157, TB-500, CJC-1295, Ipamorelin, Thymosin Alpha-1, KPV, Epitalon, Selank, Semax, MOTS-C, and others.
GLP-1 Compounding BANNED
Semaglutide and tirzepatide off shortage list. Novo Nordisk and Eli Lilly actively suing compounders. ITC General Exclusion Order blocking tirzepatide imports.
RFK Reclassification Catalyst
HHS Secretary Kennedy announced ~14 peptides will return to Category 1 — NOT YET IMPLEMENTED. Cannot build a plan around it, but must be positioned to capitalize within 24–48 hours of announcement.
Section 03
What Can and Cannot Be Compounded Today
✅ Legally Compoundable (503A)
🚫 BANNED from Compounding (Cat 2)

DO NOT TOUCH: Semaglutide, Tirzepatide — off shortage list, active litigation from Novo Nordisk and Eli Lilly.
Section 04
Our Competitive Advantages
Direct API Sourcing
Existing relationship with premier Chinese manufacturer provides 50–80% cost advantage over US distributors. Logistics already established.
Deep Marketing Expertise
15+ years of digital marketing, SEO, CRM, workflow automation, and B2B sales. Existing clinic relationships from prior client work.
$3–5M Committed Capital
Sufficient for full 503A launch and early 503B development. PIC candidates already sourced.
San Diego Biotech Ecosystem
2,000+ life science companies, 76,000 workers, $56B economic output, UCSD talent pipeline.
Market Timing
Competitors shutting down (Peptide Sciences, Amino Asylum), creating a supply vacuum while demand accelerates.
Dual Brand Architecture
ROVN (men's) and VYXN (women's) for targeted, gender-specific market positioning.
Section 05
Brand Architecture — ROVN + VYXN

Key Differentiator: Gender-specific formulations based on dermatological science — male skin is 20% thicker, 2x sebum production, lower pH. Female skin thins dramatically post-menopause. No other peptide skincare brand reformulates for these differences. Positioned between Peter Thomas Roth ($65) and SkinCeuticals ($150).
Section 06
Cosmetic Product Line Deep Dive
Launch Products — 4 SKUs per brand (8 total), all at 87%+ gross margins:
COGS Advantage
GHK-Cu from US suppliers: $25–75/gram. Our China direct cost: $8–15/gram. Savings of $10–36 per unit. Most DTC brands buy pre-formulated at 3–5x raw material cost.
Why Cosmetics First
  • Zero regulatory barrier — cosmetic, not drug
  • Revenue within 60–90 days
  • Sell on Shopify, Amazon, retail channels
  • Builds customer base that converts to pharmacy patients
Section 07
Business Model — Three-Phase Vertical Integration
Phase 1: Cosmetics
Launch and establish the initial e-commerce cosmetics line.
Phase 2: Compounding
Expand into specialized pharmacy compounding services.
Phase 3: 503B Facility
Develop a full-scale manufacturing facility for production.
Each phase builds on the last — cosmetics fund pharmacy build-out, pharmacy revenue funds the 503B facility. Revenue channels span D2C cosmetic, D2C prescription, B2B wholesale, affiliate marketing (10–20% commission), and private label white-labeling for clinics.
Section 08
Four Strategic Approaches Analyzed
The original plan — generating early cash flow through research compound e-commerce — faces extreme legal risk. Multiple companies executing this exact model have been raided, shut down, or criminally prosecuted. The core tension: Phase 1 enforcement permanently kills Phases 2 and 3.
Compliance-First Accelerator
Skip research compounds. Fast-track pharmacy. Zero risk, longest runway to revenue.
Cosmetic Bridge + Pharmacy
Launch cosmetic brand immediately. Build pharmacy in parallel. Early revenue, zero risk.
Research Compounds + Max Armor
Original plan with $500K+ legal defense reserves. Fastest revenue but EXTREME risk.
Hybrid (RECOMMENDED)
Cosmetic bridge + accelerated pharmacy + reclassification-ready infrastructure.
Approach A
Approach A -
Compliance-First Accelerator
Skip research compounds entirely. Redirect all capital toward building a licensed 503A pharmacy as fast as possible. Zero regulatory risk.
Timeline
Months 1–2
Legal foundation, entity formation, PIC recruitment
Months 2–7
Facility lease, cleanroom build-out, equipment installation
Months 7–12
Qualification, validation, CA BOP inspection and license
Months 12–36
Scale D2C, expand catalog, 503B planning
Financials
1
Year 1
$60K–$180K
2
Year 2
$960K–$3M
3
Year 3
$3M–$7.8M
Pros
Zero criminal exposure, clean licensing record, capital preservation, standard payment processing, positioned for reclassification.
Cons
No revenue for 9–15 months, $500K–$700K upfront burn, limited initial catalog, requires partner patience.

Risk Rating: LOW-MODERATE | Legal: VERY LOW | Financial: MODERATE
Approach B
Approach B -
Cosmetic Bridge + Pharmacy
Launch ROVN and VYXN cosmetic peptide brands immediately (60–90 days) as a revenue bridge while building the 503A pharmacy in parallel. Under the FD&C Act, cosmetics require no FDA pre-market approval, prescriptions, or pharmacy licenses.
How Cosmetics Feed the Pharmacy Pipeline
2–4%
Website visitor → cosmetic customer
60–80%
Cosmetic customer → email subscriber
5–15%
Email subscriber → telehealth inquiry
40–60%
Telehealth inquiry → active patient
Financials
  • Year 1: $250K–$700K
  • Year 2: $1.7M–$4.4M
  • Year 3: $3.4M–$7.8M
Key Milestones
  • Month 3: First cosmetic revenue ($5K–$16K/month)
  • Months 4–12: Scale cosmetics to $30K–$80K/month
  • Months 9–15: Pharmacy goes live
  • Months 15–36: Full dual-channel operations

Risk Rating: LOW | Legal: VERY LOW | Financial: LOW-MODERATE
Approach C
Approach C -
Research Compounds with Maximum Armor

⚠️ IMPORTANT: Research strongly advises AGAINST this approach.
"Maximum Armor" Costs
  • Complete entity insulation between research and pharmacy
  • Sell ONLY to verified research institutions
  • $500K+ liquid legal defense reserves locked away
  • Criminal defense counsel retained on standby before launch
  • Pre-launch legal opinion: $25K–$50K
  • Full-time compliance officer: $50K–$100K/year
  • Total armor cost: $620K–$765K before selling a single product
Precedent Cases
Peptide Sciences
$7.4M/month — voluntarily shut down; model no longer viable
Tailor Made Compounding
$1.79M forfeiture, 3yr probation + 4mo house arrest
All American Peptide
$3M+ forfeiture, guilty plea
Amino Asylum
FDA warehouse raid, site went offline

Risk Rating: EXTREME | Phase 1 enforcement permanently kills Phases 2 and 3. Criminal conviction automatically disqualifies pharmacy license applicants.
Recommended
Approach D — Hybrid (RECOMMENDED)
Cosmetic Bridge + Accelerated Pharmacy + Reclassification-Ready Infrastructure. Three simultaneous workstreams delivering zero legal risk, revenue in 60–90 days, and the highest risk-adjusted return of all four approaches.
Workstream 1
Launch ROVN + VYXN cosmetic e-commerce immediately — revenue in 60–90 days
Workstream 2
Fast-track 503A pharmacy — license applications and construction begin Day 1
Workstream 3
Build reclassification-ready infrastructure (dormant) — SOPs, API inventory, prescriber education for all 14 target peptides

The Reclassification Edge: SOPs drafted, stability data completed, API inventory stored, marketing materials ready but unpublished. Result: Begin compounding reclassified peptides within 24–48 hours of official FDA announcement. Competitors will need weeks to months.
Recommended
Approach D — Financial Projections
WITHOUT Reclassification (Conservative)
  • Year 1: $360K–$1.2M
  • Year 2: $1.7M–$3.6M
  • Year 3: $3.4M–$6.2M
WITH Reclassification (Bull Case)
  • Year 1: $360K–$1.2M
  • Year 2: $3.1M–$6M
  • Year 3: $8.2M–$15.6M
Why Approach D Wins
Zero Legal Risk
Partners' personal freedom is never at risk. Insurance fully obtainable at standard rates.
Revenue in 60 Days
Cosmetics generate cash flow immediately. No capital wasted on legal defense reserves.
Highest Risk-Adjusted Return
Wins in both conservative and bull scenarios. Builds maximum long-term enterprise value.
Side-by-Side Comparison Matrix
Risk-Adjusted Return Analysis

Approach D delivers the highest risk-adjusted return ($5.6M blended) regardless of whether reclassification occurs. Approach C's 40% probability of achievement (due to enforcement risk) collapses its risk-adjusted revenue to just $2.2M.
Section 9
Product Line Strategy — Risk-Tiered Catalog
Tier 1 — Safe Bets
Launch Immediately
  • GHK-Cu Topical (cosmetic)
  • Argireline + Matrixyl Serums
  • NAD+ (all forms)
  • Sermorelin, Gonadorelin
  • Bacteriostatic Water
Tier 2 — High Upside
Ready Upon Reclassification
  • BPC-157 (highest demand)
  • TB-500, Thymosin Alpha-1
  • Epitalon, Semax, Selank, KPV
  • AOD-9604, MOTS-c
  • GHK-Cu Injectable
Tier 3 — Calculated Gambles
Evaluate Carefully
  • CJC-1295/Ipamorelin (regulatory limbo)
  • PT-141 (must justify vs Vyleesi)
  • Tesamorelin (BLA complications)
  • VIP (Category 1 but threatened)
Tier 4 — Do Not Touch
Too Risky Under Any Circumstance
  • Semaglutide, Tirzepatide
  • Melanotan II (melanoma risk)
  • MK-677 (CHF signal)
  • GHRP-2/GHRP-6 (death reports)
  • Dihexa, PEG-MGF, Tesofensine
Pre-Built Protocol Bundles (Pharmacy Phase 2): "Wolverine" Injury Recovery ($500–$800/mo) | Anti-Aging Core ($400–$600/mo) | Metabolic Reset ($400–$700/mo) | Cognitive Performance ($300–$500/mo) | Immune Optimization ($600–$1,000/mo) | Sexual Wellness Men ($200–$350/mo) | Sleep and Recovery ($500–$800/mo)
Section 10
Revenue Channels and Margin Analysis
Cosmetic E-Commerce (Phase 1)
COGS: $7–$18/unit | Retail: $49–$89 | Gross margin: 70–88%
Shopify + Amazon + affiliate. Subscription revenue with strong retention.
503A Pharmacy D2C (Phase 2)
Total COGS: $16–$41/vial | D2C retail: $120–$350/vial | Gross margin: 87%
Net contribution after shipping + CAC: 54–61%
503B Wholesale B2B (Phase 3)
COGS at scale: $10–$22/vial | Wholesale: $45–$100 | Gross margin: 78%
Monthly recurring revenue from clinic accounts. Medspas expect 2–3x markup to patients.
Affiliate + Private Label
Affiliate: 10–20% commission; 15–25% of e-commerce revenue. Private label: $50K–$400K/month at scale. Research peptide customers spend $15K–$50K annually with 85%+ retention.
Section 11
3-Year Financial Projections — Approach D
3-Year Revenue Summary
EBITDA Trajectory
  • Year 1: -$402,500 (investment phase)
  • Year 2: +$480,000 (15% margin)
  • Year 3: +$1,727,000 (22% margin)
Break-Even
  • Cosmetics only: Month 5–6 (~$35K–$47K/mo)
  • Full operations: Month 22–26
  • Self-sustaining: Month 18–24
Section 12
Capital Allocation — $4M Budget

503B build-out may require supplemental financing. Industry benchmarks: $6–7M minimum. SBA 7(a) loans up to $5M available.
Capital Call Schedule
1
Call 1 — Month 0
$500K | Phase 0 legal foundation + cosmetic brand launch
2
Call 2 — Month 4
$500K | Cosmetic scaling + Phase 2 pharmacy planning
3
Call 3 — Month 8
$750K | 503A facility build-out and equipment
4
Call 4 — Month 12
$750K | 503A operations launch + full staffing
5
Call 5 — Month 18
$750K | 503B facility initiation
6
Call 6 — Month 24
$750K | 503B facility completion
Capital calls are staged to preserve partner liquidity. Phase 1–2 revenue should offset later capital needs. If cosmetic brand exceeds projections, Calls 5 and 6 may be reduced. Total reserves held: $750K (general contingency $400K + regulatory $200K + market pivot $150K).
Section 13
Entity Structure and Legal Insulation
Multi-Entity Holding Structure (Wyoming + California)
Why Wyoming for Holding Entities
  • No state income tax
  • Strongest charging order protection
  • Strong privacy protections
  • $60/year annual report fee
Critical Insulation Rules
  • Separate bank accounts, EINs, and insurance per entity
  • No shared employees between segments
  • Arm's-length inter-company transactions with written agreements
  • Each entity adequately capitalized
Formation: $20K–$35K initial | $17K–$27K annual maintenance (including $4,800 CA franchise tax for 6 entities)
Section 14
Facility and Location Strategy — San Diego
San Diego ecosystem: 2,000 life science companies | 76,000 workers | $56B economic output | $3.6B VC deployed in 2024. UCSD produces more STEM graduates annually than Stanford and UC Berkeley combined.
Miramar / Mira Mesa ⭐ Recommended
$10–$14/sq ft annually. Strong industrial base. FedEx facility nearby. Best for Phase 1–2 transitional facility.
Kearny Mesa
$14–$18/sq ft. Central location, excellent highway access. Best for smaller Phase 2 operations.
Sorrento Valley
$16–$24/sq ft. Premier life science corridor near UCSD. Existing cleanroom spaces may reduce build-out costs.

Phase 2 (503A): 1,500–3,000 sq ft, USP 797-compliant cleanroom. Phase 3 (503B): 5,000–10,000 sq ft at a SEPARATE location (CA BOP prohibits concurrent 503A/503B at same site). HVAC commissioning is the #1 cause of delays — use pharmaceutical HVAC contractors only.
Section 15
Telehealth Prescriber Network
Primary Platform: DrCare247
  • Purpose-built for D2C telehealth-to-pharmacy workflow
  • Direct compounding pharmacy integration via DoseSpot e-prescribing
  • Full white-label capability for branded ROVN/VYXN patient portals
  • Dual-mode: synchronous video + asynchronous evaluation
  • Nationwide physician network for rapid launch
  • Cost: $200–$500/provider/month
Secondary: WellSync (Scale Phase)
End-to-end white-labeled virtual care. LegitScript certified. Powered The Vitamin Shoppe's telehealth service.
Patient Flow Design
01
Visit
Customer visits ROVN or VYXN website
02
Questionnaire
Completes health questionnaire via white-label DrCare247 portal
03
Consult
Asynchronous physician review or synchronous video consultation
04
Rx
Prescription sent directly to in-house pharmacy
05
Ship
Pharmacy compounds and ships directly to patient (cold chain)
Section 16
Supply Chain and API Quality
Primary Supplier
Chinese API manufacturer (existing relationship) — 50–80% cost advantage over US distributors. Logistics already established.

CRITICAL: FDA registration status MUST be verified immediately. If unregistered, cannot be used for pharmacy compounding in Phases 2 and 3.
Supply Chain Risk Mitigation
  • Qualify 2–3 backup US-based FDA-registered suppliers
  • Maintain 3-month safety stock inventory
  • Cold chain logistics required (2–8°C)
  • Third-party COA testing for every batch through accredited US lab
API Quality Requirements for Pharmacy Compounding

"Research Use Only" grade APIs CANNOT be used in human compounding. Pharmaceutical/cGMP grade is REQUIRED for all pharmacy operations.
Section 17
Risk Register
Critical Risks
High Risks — Key Mitigations
CA BOP Licensing Delays (4–12 months)
Submit applications immediately; engage pharmacy consultant; have all documentation prepared in advance.
FTC Enforcement Against Marketing Claims
Attorney review of all marketing copy; no unsubstantiated health claims; cosmetic claims only.
Anti-Kickback Violations in Telehealth
Fixed-fee MSA; arm's-length structure; specialist healthcare attorney.
PIC Departure Disrupts Pharmacy Operations
Competitive compensation ($143K–$165K + $25K retention bonus); backup PIC candidate identified.
Section 18
36-Month Roadmap
Months 1–2: Triple Launch
Form all 7 entities. Retain pharmaceutical regulatory attorney. Verify Chinese API supplier FDA registration. Begin ROVN/VYXN cosmetic brand development with CA Botana. Begin PIC recruitment. File CA BOP pre-consultation request. File trademark applications.
Months 2–6: Revenue + Build
First cosmetic revenue: $15K–$40K/month. Email list: 2,000–5,000 subscribers. Facility lease signed. Cleanroom construction begins. Reclassification-ready SOPs drafted for 14 target peptides. 3–5 physicians contracted.
Months 6–12: Construction + Pharmacy Go-Live
Cosmetic revenue: $30K–$60K/month. Cleanroom qualification and validation. CA BOP pharmacy license obtained. Pharmacy soft launch: Sermorelin, NAD+ (4 formats), GHK-Cu Rx, PT-141. Combined revenue: $60K–$120K/month.
Months 12–18: Dual Revenue Scale
Cosmetics: $60K–$100K/month. Pharmacy D2C: $60K–$200K/month. IF reclassification occurs: immediately add BPC-157, TB-500, Thymosin Alpha-1. Revenue with reclassification: $200K–$400K/month.
Months 18–36: Full Vertical Integration
Operations self-funded from revenue. 503B construction and validation complete. Multi-state licensing (20–40 states). B2B wholesale launches with pre-committed clinic customers. Year 3 annualized revenue: $5M–$10M+. EBITDA margin: 20–25%.
Section 19
Immediate Next Steps — Next 30 Days
Week 1: Legal and Strategic
  1. Retain pharmaceutical regulatory attorney (Frier Levitt, Holt Law, or Cohen Healthcare Law Group)
  1. Verify Chinese API manufacturer FDA registration — check FDA Drug Establishment Registration database
  1. All partners reach consensus on Approach D
Week 2: Entity Formation
  1. Engage business formation attorney — draft and file all 7 entities
  1. Apply for EINs for all formed entities
  1. Open separate business bank accounts per entity
  1. File trademark applications for ROVN and VYXN
Week 3: Operations Launch
  1. Begin PIC recruitment via pharmacy-specific job boards
  1. Engage commercial real estate broker — Miramar, Kearny Mesa, Sorrento Valley
  1. Begin cosmetic brand development — select CA Botana, set up Shopify, place formulation orders
  1. File CA Board of Pharmacy pre-consultation request
Week 4: Strategic Positioning
  1. Begin prescriber network outreach — identify 5–10 physicians
  1. Engage specialty insurance broker — GL, product liability, D&O, cyber
  1. Set up daily regulatory monitoring: FDA Federal Register, PCAC, RFK updates, AB 2442, OFA v. FDA
  1. Schedule 30-day partner check-in meeting
Section 20
The Exit Opportunity
What We Are Building Is Highly Acquirable
  • Licensed, multi-channel peptide wellness company
  • Dual premium DTC brands (ROVN + VYXN) with proven cosmetic revenue
  • Operational 503A pharmacy with established telehealth network
  • 503B outsourcing facility (operational or in construction)
  • Reclassification-ready infrastructure — first-mover advantage
  • Direct API sourcing providing structural cost advantage
  • Valuable IP portfolio (trademarks, domains, formulations, SOPs)
Potential Acquirers
  • Hims and Hers ($2.35B revenue, 2.5M subscribers)
  • Empower Pharmacy (largest US compounding pharmacy)
  • Telehealth platforms seeking pharmacy vertical integration
  • PE-backed pharmacy rollup groups
  • Life science companies seeking D2C peptide channel
5–8x
EBITDA Multiple
Potential exit valuation range
$28M
Max Exit Value
At Year 3 with reclassification upside